Declines in Opioid Prescribing After a Private Insurer Policy Change — Massachusetts, 2011–2015
October 21, 2016
Unintentional opioid-related overdose deaths, including deaths involving heroin, increased 45% in Massachusetts from 2012 to 2013. Private insurer Blue Cross Blue Shield of Massachusetts implemented a comprehensive opioid utilization program in 2012. Monthly opioid prescribing rates and the percentage of members with opioid prescriptions declined significantly following implementation.
National Progress Toward Hepatitis C Elimination — Georgia, 2015–2016
October 21, 2016
The country of Georgia has a high prevalence of hepatitis C virus (HCV) infection. The Georgia HCV Elimination Program began in April 2015. During the program’s first year, 27,392 persons enrolled in the treatment program, and 8,448 initiated treatment with direct-acting antivirals. Most persons (92.8%) who began treatment had advanced liver disease. Among 2,398 persons who completed treatment and were tested to determine treatment response, more than 80% were cured of their HCV infection.
Summary of Notifiable Infectious Diseases and Conditions — United States, 2014
October 14, 2016
Health-care providers in the United States are required to report certain infectious diseases to a specified state or local authority. A disease is designated as notifiable if timely information about individual cases is considered necessary for prevention and control of the disease. Each year, CDC publishes a summary of the cases of notifiable disease reported for the most recent year for which data is available. This report presents a summary of notifiable diseases for 2014.
Summary of Notifiable Noninfectious Conditions and Disease Outbreaks
October 14, 2016
The 2016 Summary of Notifiable Noninfectious Conditions and Disease Outbreaks — United States contains official statistics for the occurrence of nationally notifiable noninfectious conditions and disease outbreaks and is published for the second time in the same volume of MMWR as the annual Summary of Notifiable Infectious Diseases and Conditions. The summary includes seven chapters addressing the following subjects: acute pesticide-related illness and injury arising from occupational exposure, acute nonoccupational pesticide-related illness and injury, cancer, elevated blood lead levels among children, elevated blood lead levels among adults, silicosis, and foodborne and waterborne disease outbreaks. CDC’s Center for Surveillance, Epidemiology, and Laboratory Services (CSELS) coordinated the development and publication of this annual summary.
National Estimates of Marijuana Use and Related Indicators — National Survey on Drug Use and Health, United States, 2002–2014
September 2, 2016
Marijuana is the most commonly used illicit drug in the United States. In 2013, 7.5% (19.8 million) of the U.S. population aged ≥12 years reported using marijuana during the preceding month. Because of certain state-level policies that have legalized marijuana for medical or recreational use, population-based data on marijuana use and other related indicators are needed to help monitor behavioral health changes. This report describes national trends for prevalence of marijuana use; initiation; perception of harm risk, approval, and attitudes; perception of availability and mode of acquisition; dependence and abuse; and perception of legal penalty for marijuana possession.
Recommendations and Reports
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2016–17 Influenza Season
August 26, 2016
This report updates the 2015–16 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza. Routine annual influenza vaccination is recommended for all persons aged ≥6 months. For the 2016–17 influenza season, inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Recombinant influenza vaccine (RIV) will be available in a trivalent formulation (RIV3). In light of concerns regarding poor effectiveness against influenza A(H1N1)pdm09 in the United States during the 2013–14 and 2015–16 seasons, for the 2016–17 season, ACIP makes the interim recommendation that live attenuated influenza vaccine (LAIV4) should not be used. Vaccine virus strains included in the 2016–17 U.S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1)–like virus, an A/Hong Kong/4801/2014 (H3N2)–like virus, and a B/Brisbane/60/2008–like virus (Victoria lineage). Quadrivalent vaccines will include an additional influenza B virus strain, a B/Phuket/3073/2013–like virus (Yamagata lineage). These recommendations apply to all licensed influenza vaccines used within Food and Drug Administration–licensed indications, including those licensed after the publication date of this report. Updates and other information are available at CDC’s influenza website (http://www.cdc.gov/flu). Vaccination and health care providers should check CDC’s influenza website periodically for additional information.
CDC’s Response to the 2014–2016 Ebola Epidemic — West Africa and United States
July 8, 2016
This historic 2014-2016 Ebola Epidemic in West Africa required a massive international response by multiple partners to assist the affected countries. This supplement present reports that chronicle major aspects of CDC’s response to the Ebola epidemic.
- Page last reviewed: October 20, 2016
- Page last updated: October 20, 2016
- Content source: